Compare Kyndryl Holdings Inc (KD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Repligen Corporation Common Stock — how do they compare? Kyndryl Holdings Inc trades at $11.78 (market cap $2.57B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 4.4× Kyndryl Holdings Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Repligen Corporation Common Stock for 0 Days on average.
| KD | RGEN | |
|---|---|---|
Market Cap | $2.57B | $11.31B |
Volume | 3,294,342 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $28.92 | $194.57 |
52-Week Low | $10.59 | $102.87 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $5.39B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $12.24, up 3.9% on the day, with a neutral technical signal and bearish moving averages. The company reported a return to profitability in 2025 with net income of $252 million, though revenue has declined from prior years. Recent news highlights a strategic focus on AI, including the launch of an innovation lab and an acquisition to bolster healthcare IT services. Positive cash flow generation and a low EV/EBITDA of 3.8 suggest underlying value, but consecutive earnings misses and a high P/E ratio of 31.9 present challenges.
The investment outlook is mixed. A consensus price target of $14.67 implies potential upside, supported by strong operational cash flow and debt reduction. However, risks include declining revenue, thin net margins, and a majority 'Hold' analyst rating. The stock's performance hinges on successful execution of its AI strategy and reversing the top-line contraction seen in recent years.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
